RT Journal Article
SR Electronic
T1 Gene prioritization based on systems biology revealed new insight into genetic basis and pathophysiology underlying schizophrenia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.26.20140541
DO 10.1101/2020.06.26.20140541
A1 Li, Jia-Feng
A1 Wang, Lei
A1 Dang, Xiao
A1 Feng, Wei-Min
A1 Wang, Zi-Wei
A1 Ma, Yu-Ting
A1 He, Si-Jie
A1 Liang, Liang
A1 Yang, Huan-Ming
A1 Liu, Han-Kui
A1 Zhang, Jian-Guo
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.26.20140541.abstract
AB Sequencing-based studies have recognized hundreds of genetic variants that increase the risk of schizophrenia (SCZ), but only a few percents of heritability can be attributed to these loci. It is challenging to discover the full spectrum of schizophrenia genes and reveal the dysregulated functions underlying the disease. Here, we proposed a holistic model for predicting disease genes (HMPDG), a novel machine learning prediction strategy integrated by Protein-Protein Interaction Network (PPIN), pathogenicity score, and RNA expression data. Applying HMPDG, 1946 potential risk genes (PRGs) as a complement of the genetic basis of SCZ were predicted. Among these, the first decile genes were highlighted as high confidence genes (HCGs). PRGs were validated by multiple independent studies of schizophrenia, including genome-wide association studies (GWASs), gene expression studies, and epigenetic studies. Remarkably, the strategy revealed causal genes of schizophrenia in GWAS loci and regions of copy number variant (CNV), providing a new insight to identify key genes in disease-related loci with multi genes. Leveraging our predictions, we depict the spatiotemporal expression pattern and functional groups of schizophrenia risk genes, which can help us figure out the pathophysiology of schizophrenia and facilitate the discovery of biomarkers. Taken together, our strategy will advance the understanding of schizophrenia genetic basis and the development of diagnosis and therapeutics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Shenzhen Municipal of Government of China (NO. JCYJ20170412153248372), Shenzhen Municipal of Government of China (NO. JCYJ20180507183615145), The National Key R&D Program of China (NO.2016YFC1305900), The National Key R&D Program of China (NO.2017YFC1308402), The National Natural Science Foundation of China (NO.81771444).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of BGI has approved this study .NO.FT20044All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from https://decipher.sanger.ac.uk and via email from decipher{at}sanger.ac.uk. Funding for the DECIPHER project was provided by Wellcome